72934-40-8

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1-(4-Methoxyphenyl)cyclopropanamine is used as a key intermediate in the synthesis of new drugs and pharmaceuticals. Its unique chemical structure allows for the development of compounds with novel therapeutic properties and potential applications in various medical fields.
Used in Organic Synthesis:
1-(4-Methoxyphenyl)cyclopropanamine serves as a valuable building block in organic synthesis, enabling the production of a wide range of organic compounds through synthetic processes. Its cyclopropane ring and amino group provide opportunities for further functionalization and modification, leading to the creation of diverse chemical entities with potential applications in various industries.
Used in Medicinal Chemistry and Drug Design:
Due to its distinctive chemical structure and properties, 1-(4-Methoxyphenyl)cyclopropanamine holds promise in the field of medicinal chemistry and drug design. It can be utilized to explore new chemical space and identify potential drug candidates with improved pharmacological profiles, selectivity, and efficacy.

InChI:InChI=1/C10H13NO/c1-12-9-4-2-8(3-5-9)10(11)6-7-10/h2-5H,6-7,11H2,1H3

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 874-90-8 4-methoxybenzonitrile 
• 16728-01-1 1-(4-methoxyphenyl)-1-cyclopropanecarboxylic acid 

Downstream Products

• 65374-28-9 1-Azido-1-(4-methoxyphenyl)-cyclopropan 
• 1266158-02-4 4-(1-aminocyclopropyl)phenol 
• 1394918-80-9 C₁₄H₁₉NO₃ 
• 1357456-14-4 C₃₀H₃₅ClN₄O₂S 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

A direct synthesis of 1-aryl- and 1-alkenylcyclopropylamines from aryl and alkenyl nitriles

The reaction of various aromatic nitriles with 1.1 equiv of Ti(Oi-Pr)4 and 2.2 equiv of EtMgBr followed by addition of a Lewis acid gave 1-aryl cyclopropylamines in 43-76% yields. Under similar conditions, conjugated alkene-nitriles afford 1-alkenylcyclopropylamines (42-65%).

3-[5-substituted benzyl)amino]-2-phenylpiperidines as substance P antagonists

This invention provides a compound of the formula: STR1 and its pharmaceutically acceptable salts, wherein R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, halo C 1 -C 6 alkyl or terahydropyranyl, having one or more substituents selected from cyano, 1,3-thiazolanyl, COOR 2, COR 2, OCOR 2, CONR 3 R 4, NR 3 R 4, NR 5 COR 3 and C.ident.CR 6, wherein R 2 is hydrogen or C 1 -C 4 alkyl, R 3 and R 4 are independently hydrogen, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl, R 5 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl and R 6 is hydrogen, halo, cyano, C 1 -C 6 alkyl, COOH, COO(C 1 -C 4 alkyl) or phenyl; X is C 1 -C 6 alkoxy or halo C 1 -C 6 alkoxy; and Ar is phenyl optionally substituted with halo.These compounds are useful in the treatment of allergic disorders, angiogenesis, gastrointestinal disorders, central nervous system disorders, inflammatory diseases, emesis, urinary incontinence, pain, migraine, sunburn, and diseases, disorders and adverse conditions caused by Helicobacter pylori, in a mammalian subject.